PL3773589T3 - Inhibitor RET do stosowania w leczeniu raka ze zmianą RET - Google Patents

Inhibitor RET do stosowania w leczeniu raka ze zmianą RET

Info

Publication number
PL3773589T3
PL3773589T3 PL19718531.7T PL19718531T PL3773589T3 PL 3773589 T3 PL3773589 T3 PL 3773589T3 PL 19718531 T PL19718531 T PL 19718531T PL 3773589 T3 PL3773589 T3 PL 3773589T3
Authority
PL
Poland
Prior art keywords
ret
treatment
inhibitor
altered cancer
altered
Prior art date
Application number
PL19718531.7T
Other languages
English (en)
Inventor
Erica EVANS RAAB
Beni B. Wolf
Original Assignee
Blueprint Medicines Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66223846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3773589(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blueprint Medicines Corporation filed Critical Blueprint Medicines Corporation
Publication of PL3773589T3 publication Critical patent/PL3773589T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL19718531.7T 2018-04-03 2019-04-03 Inhibitor RET do stosowania w leczeniu raka ze zmianą RET PL3773589T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862652284P 2018-04-03 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US201862741683P 2018-10-05 2018-10-05
PCT/US2019/025655 WO2019195471A1 (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Publications (1)

Publication Number Publication Date
PL3773589T3 true PL3773589T3 (pl) 2024-04-02

Family

ID=66223846

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19718531.7T PL3773589T3 (pl) 2018-04-03 2019-04-03 Inhibitor RET do stosowania w leczeniu raka ze zmianą RET

Country Status (26)

Country Link
US (5) US20210100795A1 (pl)
EP (2) EP4353317A3 (pl)
JP (3) JP7422084B2 (pl)
KR (1) KR20200139749A (pl)
AU (1) AU2019247766A1 (pl)
BR (1) BR112020020273A2 (pl)
CA (1) CA3096043A1 (pl)
CL (1) CL2020002544A1 (pl)
CR (1) CR20200522A (pl)
DK (1) DK3773589T3 (pl)
ES (1) ES2970041T3 (pl)
FI (1) FI3773589T3 (pl)
HR (1) HRP20240124T1 (pl)
HU (1) HUE065374T2 (pl)
IL (1) IL277629A (pl)
LT (1) LT3773589T (pl)
MX (1) MX2020010417A (pl)
MY (1) MY203645A (pl)
PE (1) PE20210096A1 (pl)
PL (1) PL3773589T3 (pl)
PT (1) PT3773589T (pl)
RS (1) RS65127B1 (pl)
SG (1) SG11202009681YA (pl)
SI (1) SI3773589T1 (pl)
WO (1) WO2019195471A1 (pl)
ZA (1) ZA202006072B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
US11946935B2 (en) * 2020-08-25 2024-04-02 Regents Of The University Of Minnesota Circulating tumor markers for meningiomas
JP1746261S (ja) * 2022-10-17 2023-06-14 量子暗号鍵伝送機

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
WO2004009087A1 (en) 2002-07-24 2004-01-29 University Of Cincinnati 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
WO2006128042A2 (en) 2005-05-26 2006-11-30 The Johns Hopkins University Methods of identifying mutations in nucleic acid
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007087245A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Ret tyrosine kinase inhibition
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
BRPI0814441A2 (pt) 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
EP2313091A4 (en) 2008-07-14 2012-04-04 Univ Kingston PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
AU2010229140A1 (en) 2009-03-24 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
EP2440052A4 (en) 2009-06-08 2013-01-23 Abraxis Bioscience Llc TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
PH12012500809A1 (en) 2009-10-30 2012-11-26 Ariad Pharma Inc Methods and compositions for treating cancer
CA2780892C (en) 2009-11-13 2017-02-14 Genosco Kinase inhibitors
WO2013018882A1 (ja) 2011-08-04 2013-02-07 独立行政法人国立がん研究センター Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
ES2645984T3 (es) 2012-04-25 2017-12-11 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de TTX-S
US20150099721A1 (en) 2012-05-10 2015-04-09 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
JPWO2014017491A1 (ja) 2012-07-26 2016-07-11 国立研究開発法人国立がん研究センター Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス， インク． 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
PL2902029T3 (pl) 2012-09-25 2019-01-31 Chugai Seiyaku Kabushiki Kaisha Inhibitor RET
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MX2015012286A (es) 2013-03-15 2016-05-31 Glaxosmithkline Ip Dev Ltd Derivados de piridina como inhibidores de cinasa reordenada durante transfección.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
WO2014147640A2 (en) 2013-03-19 2014-09-25 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of anagliptin
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
EP3037547A1 (en) 2013-08-20 2016-06-29 National Cancer Center New fusion gene detected in lung cancer
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
EP3218378B1 (en) 2014-11-14 2020-01-08 Nerviano Medical Sciences S.r.l. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CN104844567B (zh) 2015-04-23 2017-03-29 暨南大学 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
BR112018008908A2 (pt) 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
HRP20221051T8 (hr) 2016-04-15 2023-07-21 Cancer Research Technology Limited Heterociklički spojevi kao inhibitori ret kinaze
KR102706837B1 (ko) 2016-04-15 2024-09-19 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN106749231B (zh) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 萘啶化合物和药物组合物及它们的应用
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US20210290620A1 (en) * 2017-05-15 2021-09-23 Blueprint Medicines Corporation Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
EP3641776B1 (en) 2017-06-23 2023-10-18 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (zh) 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
ES3074838T3 (es) 2017-07-07 2026-07-23 Medicover Public Co Ltd Análisis paralelo multiplexado con enriquecimiento de blancos para la evaluación de biomarcadores tumorales
CN107980784B (zh) 2017-12-13 2020-05-26 中国农业大学 5-氨基吡唑类化合物在调节植物生长方面的应用
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108341782A (zh) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 3-氨基-5-甲基吡唑的合成工艺
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
CN111440151A (zh) 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
CN111362923A (zh) 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
US20240059672A1 (en) 2020-12-04 2024-02-22 Blueprint Medicines Corporation Method of preparing pralsetinib

Also Published As

Publication number Publication date
US20250041297A1 (en) 2025-02-06
JP2022022391A (ja) 2022-02-03
EP4353317A2 (en) 2024-04-17
CA3096043A1 (en) 2019-10-10
US20210100799A1 (en) 2021-04-08
US20220175773A1 (en) 2022-06-09
JP2021520349A (ja) 2021-08-19
CR20200522A (es) 2021-02-17
US20210085680A1 (en) 2021-03-25
JP7422084B2 (ja) 2024-01-25
MX2020010417A (es) 2021-01-08
US11872192B2 (en) 2024-01-16
US11963958B2 (en) 2024-04-23
IL277629A (en) 2020-11-30
PT3773589T (pt) 2024-02-06
SG11202009681YA (en) 2020-10-29
FI3773589T3 (fi) 2024-02-01
ZA202006072B (en) 2024-01-31
HUE065374T2 (hu) 2024-05-28
BR112020020273A2 (pt) 2021-04-06
US11273160B2 (en) 2022-03-15
PE20210096A1 (es) 2021-01-12
WO2019195471A1 (en) 2019-10-10
ES2970041T3 (es) 2024-05-24
EP3773589A1 (en) 2021-02-17
EP4353317A3 (en) 2024-05-08
AU2019247766A1 (en) 2020-10-15
DK3773589T3 (da) 2024-01-29
LT3773589T (lt) 2024-02-12
MY203645A (en) 2024-07-11
RS65127B1 (sr) 2024-02-29
EP3773589B1 (en) 2023-11-01
SI3773589T1 (sl) 2024-03-29
US20210100795A1 (en) 2021-04-08
KR20200139749A (ko) 2020-12-14
HRP20240124T1 (hr) 2024-04-12
US12539303B2 (en) 2026-02-03
CL2020002544A1 (es) 2021-06-11
JP2023165937A (ja) 2023-11-17
RU2020135917A (ru) 2022-05-04

Similar Documents

Publication Publication Date Title
IL282663A (en) Bt1718 for use in treating cancer
IL284199A (en) Csf1r inhibitors for use in treating cancer
PT3902803T (pt) Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
HUE063145T2 (hu) Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra
PL3806898T3 (pl) Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
IL268676A (en) Inhibition of smarca2 for treatment of cancer
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
IL290011A (en) Ezh2 inhibition in combination therapies for the treatment of cancers
IL274445A (en) Adenosine pathway inhibitors for cancer treatment
IL279260A (en) KDM1A inhibitors for the treatment of diseases
DK3704108T3 (da) Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling
PT3773589T (pt) Inibidor de ret para utilização no tratamento de cancro com alteração de ret
EP3858943A4 (en) Surface treatment agent
PL3490560T3 (pl) Niraparyb do stosowania w sposobie leczenia nowotworu prostaty
HUE059990T2 (hu) 2-Oxo-tiazol-származékok A2A inhibitorként és a rákos megbetegedések kezelésében alkalmazható vegyületekként
PL3768284T3 (pl) Kompozycje z fageliny entrecoccus do zastosowania w terapii
IL282093A (en) Combination therapy for cancer
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
IL281845A (en) Combination therapy for the treatment of cancer
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
IL282478A (en) Materials and methods for treating cancer
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
IL288086A (en) Methods and materials for treating cancer
IL281600A (en) Methods of treating cancer